Recent years have brought significant progress in the treatment of B-cell acute
lymphoblastic leukemia (ALL). This was influenced by both the improved schemes of …

The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with
the incorporation of multi-agent chemotherapy in the treatment landscape as well as the …

Genomic profiling during the diagnosis of B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) in adults is used to guide disease classification, risk stratification, and treatment …

This retrospective observational study (NEUF) included adult patients with B-cell acute
lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of …

Abstract KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is widely recognized as a high-risk leukemia in both children and adults. However …

Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in …

Background The published literature on hematological, clinical, flowcytometric‐
immunophenotyping, and minimal residual disease outcomes of the prognostically important …

Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with
relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with …

Standard cytogenetic techniques (chromosomal banding analysis—CBA, and fluorescence
in situ hybridization—FISH) show limits in characterizing complex chromosomal …

Background The role of splicing factor‐coding gene polymorphisms in pediatric acute
lymphoblastic leukemia (ALL) susceptibility is still unclear. Methods A case–control …